| NCT ID | NCT05761314 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | RASopathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2021-10-12 |
| Primary Completion | 2023-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2021-10-12 with a primary completion date of 2023-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
RASopathies are a group of syndromes, caused by variants of genes involved in the regulation of the Ras/MAP/ERK pathway. This intracellular transduction pathway profoundly affects embryogenic development, organogenesis, synaptic plasticity and neuronal growth. RASopathies are characterized by multi-organ involvement, growth delay, premature aging and haemato-oncological manifestations. Based on evidences provided by literature, cancer screening protocols are applied in some individuals affected by RASopathies, even though detailed information about prevalence and molecular pathogenesis of such tumors is still not clearly elucidate.
Eligibility Criteria
Inclusion Criteria: * Clinical and molecularly confirmed diagnosis of a RASopathy Exclusion Criteria: * Clinical diagnosis of RASopathy without molecular characterization
Contact & Investigator
Chiara Leoni, MD, PhD
PRINCIPAL INVESTIGATOR
Fondazione Policlinico A. Gemelli, IRCCS
Frequently Asked Questions
Who can join the NCT05761314 clinical trial?
This trial is open to participants of all sexes, studying RASopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05761314 currently recruiting?
Yes, NCT05761314 is actively recruiting participants. Contact the research team at chiara.leoni@policlinicogemelli.it for enrollment information.
Where is the NCT05761314 trial being conducted?
This trial is being conducted at Roma, Italy.
Who is sponsoring the NCT05761314 clinical trial?
NCT05761314 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Chiara Leoni, MD, PhD at Fondazione Policlinico A. Gemelli, IRCCS. The trial plans to enroll 100 participants.